25 February 2020 - - US-based The CIBMTR (Center for International Blood and Marrow Transplant Research) TODAY announced the selection of IQVIA as it seeks to expand the value real world data can bring to patients, through systematic investigation to generate real world evidence, the companies said.

IQVIA (NYSE: IQV) is a company known worldwide for its expertise in building technology solutions customized for global research networks engaged in complex data exchange for clinical outcomes registries.

The CIBMTR is a long-standing research collaboration between the National Marrow Donor Program (NMDP)/Be The Match and the Medical College of Wisconsin, dedicated to improving survival, treatment and quality of life for transplant and cellular therapy patients.

The engagement with IQVIA will enable accelerated progress towards a shared vision to optimize real world data for the benefit of providers, potential bone marrow donors and recipients and other stakeholders.

Together, the parties will create a real world data acquisition capability that will transform the ability of the CIBMTR to collect data from its global network partners.

In addition, extensive metadata development is planned to generate specified information to improve the accessibility and efficiency of tracking and manipulating data throughout analyses.

The CIBMTR (Center for International Blood and Marrow Transplant Research) is a research collaboration between the National Marrow Donor Program (NMDP)/Be The Match and the Medical College of Wisconsin.

The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy worldwide to increase survival and enrich quality of life for patients.

The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database.

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.

Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science, leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science, to enable companies to reimagine and develop new approaches to clinical development and commercialisation, speed innovation and accelerate improvements in healthcare outcomes.

Powered by the IQVIA CORE, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities.

With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is in protecting individual patient privacy.

The company uses a range of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analysing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes.

IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviours and scientific advances, in an effort to advance their path toward cures.

The National Marrow Donor Program (NMDP)/Be The Match is a leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia and lymphoma, as well as other diseases.

The NMDP/Be The Match manages the world's largest registry of potential blood stem cell donors and cord blood units, connects patients to their donor match for a life-saving marrow or umbilical cord blood transplant and educates health care professionals and patients.

In 2016, the NMDP/Be The Match established Be The Match BioTherapies to accelerate patient access to life-saving therapies, by providing proven services and support to companies developing and delivering cell and gene therapies.